STOCK TITAN

PMV Pharmaceuticals (PMVP) DEF 14A Filings

PMVP NASDAQ

Here are the DEF 14A proxy statements from PMV Pharmaceuticals, Inc (PMVP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PMVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMVP filings page.

Rhea-AI Summary

PMV Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026 at 10:00 a.m. Eastern. Investors will elect two Class III directors, David H. Mack, Ph.D. and Laurie Stelzer, approve on a non-binding basis executive pay, and ratify Ernst & Young LLP as auditor for 2026.

The company will reduce its board from seven to six members as chair Richard Heyman, Ph.D. departs, and plans for director Laurie Stelzer to become board chair while David Mack remains CEO. The proxy describes Nasdaq independence compliance, committee structures, ESG oversight and detailed director compensation.

The filing also reviews 2025 executive pay, including total 2025 compensation of $1.7 million for CEO David Mack, and explains the prior 2025 say-on-pay failure, linking stockholder concerns mainly to a 2024 employee-only option exchange the board views as a one-time event.